Search research articles
Contact Us
Filters
Showing results (191-200 of 217) with videos related to
Page
of 22
Sort By:
The International Journal of Biological Markers
|
June 8, 2018
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin
Heejung Chae, Hyungwoo Cho, Changhoon Yoo, et al.
Investigational New Drugs
|
April 5, 2018
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Jihoon Kang, Inhwan Hwang, Changhoon Yoo, et al.
Therapeutic Advances in Medical Oncology
|
September 28, 2020
FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
Changhoon Yoo, Inhwan Hwang, Tae Jun Song, et al.
Therapeutic Advances in Medical Oncology
|
May 16, 2022
Real-world outcomes of adjuvant gemcitabine <i>versus</i> gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
Sora Kang, Changhoon Yoo, So Heun Lee, et al.
Cancer Research and Treatment
|
March 14, 2023
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
So Heun Lee, Dae Wook Hwang, Changhoon Yoo, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
October 24, 2015
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin
Seong Joon Park, Seung-Mi Kim, Jai-Hee Moon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 3, 2019
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker
Heejung Chae, Deokhoon Kim, Changhoon Yoo, et al.
Investigational New Drugs
|
December 2, 2017
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin
Hyungwoo Cho, Changhoon Yoo, Kyu-Pyo Kim, et al.
Investigational New Drugs
|
November 1, 2013
NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants
Jae-Sik Shin, Seung-Woo Hong, Jai-Hee Moon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2024
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
Yeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 217) with videos related to
Sort By:
Page
of 22
The International Journal of Biological Markers
|
June 8, 2018
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin
Heejung Chae, Hyungwoo Cho, Changhoon Yoo, et al.
Investigational New Drugs
|
April 5, 2018
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Jihoon Kang, Inhwan Hwang, Changhoon Yoo, et al.
Therapeutic Advances in Medical Oncology
|
September 28, 2020
FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
Changhoon Yoo, Inhwan Hwang, Tae Jun Song, et al.
Therapeutic Advances in Medical Oncology
|
May 16, 2022
Real-world outcomes of adjuvant gemcitabine <i>versus</i> gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
Sora Kang, Changhoon Yoo, So Heun Lee, et al.
Cancer Research and Treatment
|
March 14, 2023
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
So Heun Lee, Dae Wook Hwang, Changhoon Yoo, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
October 24, 2015
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin
Seong Joon Park, Seung-Mi Kim, Jai-Hee Moon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 3, 2019
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker
Heejung Chae, Deokhoon Kim, Changhoon Yoo, et al.
Investigational New Drugs
|
December 2, 2017
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin
Hyungwoo Cho, Changhoon Yoo, Kyu-Pyo Kim, et al.
Investigational New Drugs
|
November 1, 2013
NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants
Jae-Sik Shin, Seung-Woo Hong, Jai-Hee Moon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2024
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
Yeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, et al.
Page
of 22